FDA finally gets a public list of what's in your food

What it does

This bill requires the FDA to create and maintain a public list of food substances that are 'generally recognized as safe' (GRAS), and mandates that companies notify the FDA before using new GRAS substances in food. Existing GRAS substances have 2 years to be listed; new ones must be reported 120 days before use. If the FDA doesn't act within 180 days, substances are automatically deemed safe and added to the list. The bill also creates a postmarket review process allowing the FDA to re-evaluate GRAS substances, food additives, and color additives if safety concerns emerge.

Why we flagged it

The bill's core function is to formalize and publicize the FDA's oversight of GRAS substances—a category that has operated largely outside public view since 1958. It shifts from a passive, company-initiated notification system to an active FDA-maintained registry with mandatory reporting and postmarket review authority.

What the text implies

• The automatic-listing provision (substances deemed safe if FDA doesn't act within 180 days) may create a de facto approval mechanism that pressures the FDA to act quickly, potentially favoring companies over thorough safety review if FDA resources are constrained.
• Postmarket review authority in Section 409B allows the FDA to reclassify GRAS substances as food additives subject to stricter section 409 requirements, retroactively changing the regulatory status of substances already in use—potentially disrupting supply chains and imposing compliance costs on manufacturers.
• The bill does not specify funding or staffing increases for the FDA to handle the new listing, review, and postmarket assessment workload, creating a potential implementation gap.
• State governmental officials gain standing to petition for postmarket review, decentralizing safety decisions and potentially creating conflicting state-level regulatory pressure on manufacturers.
• The definition of GRAS is narrowed by excluding food additives already subject to section 409, but the boundary between GRAS and food additive becomes a contested regulatory classification that may spawn litigation.

Who it affects

Ordinary consumers gain transparency and FDA oversight of food substances previously approved without public disclosure or formal listing. The mandatory reporting requirement and automatic-listing mechanism create accountability where none existed before, while postmarket review allows the FDA to remove unsafe substances. The 2-year transition period and 180-day default-approval window balance regulatory burden with public safety.

Who stands to gain

• pharmaceutical companies (regulatory clarity and potential market access for food-derived ingredient
• food manufacturers (transparency reduces liability from unlisted substances; automatic approval mech
• contract research organizations (increased demand for safety studies to support GRAS notices)
• legal/compliance consulting firms (new regulatory filing and postmarket review requirements)

Named in the bill

FDA (Food and Drug Administration), Federal Food, Drug, and Cosmetic Act, Section 409 (food additives), Section 721 (color additives), Section 409A (new GRAS listing requirement), Section 409B (postmarket assessment), Bristol Myers Squibb (BMY), Guardant Health (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ)

Where it stands

3 cosponsors: 2 Republicans, 1 Independents.

• Nov 6, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Nov 6, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

16 lobbying clients named this bill on 24 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $50,300,234 in lobbying spend. A filing names 18 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 95% of bills with at least one filing.

Roger Marshall, the sponsor, reported $1,777,391 in PAC receipts in the 2026 cycle. $8,000 of that came from 1 PAC tied to these lobbying clients.

• Chamber of Commerce of the U.S.A. — $36,700,000 on 2 filings
• Dow Chemical Company Dba Dow — $2,740,000 on 2 filings
• American Chemistry Council — $2,570,000 on 1 filing
• Bayer Corporation (consolidated Report) — $1,820,000 on 1 filing
• National Restaurant Association — $1,620,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.